Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Type 2 Diabetes (T2DM), Hypoglycemia (Di...
Phase NA
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study will offer two study interventions designed to bring on a mild low blood sugar (capillary blood glucose result 3.0 to 3.8 mmol/L), in order to study the effectiveness of each study participant's personal choice of treatment and first recheck time. The two study interventions that the participant can choose to complete (one or both interventions). Based on each participant's own experience with hypoglycemia treatment or their preferences, the participant can choose one of 4 simple carbohydrate treatment quantities, and choose one of 4 capillary blood glucose recheck times.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Recumbent Exercise Bike to induce mild hypoglycemia — The participant rides the recumbent exercise bike at their preferred speed and records the distance travelled until there is onset of mild hypoglycemia, determined by capillary blood glucose test result 3.0 to 3.8 mmmol/L. Based on each participant's own experience with hypoglycemia treatment or their preferences, the participant can choose one of 4 simple carbohydrate treatment quantities: 8 grams, 16 grams, 20 grams, 32 grams The participant can choose one of 4 capillary blood glucose recheck times: 15 minutes, 20 minutes, 25 minutes, 30 minutes.
  • Behavioral: Delaying food to induce mild hypoglycemia, — At the study visit, in front of the study nurse, the participant takes their usual clinical care dose of sulfonylurea or basal insulin. If the participant's usual clinical care includes insulin with a rapid-acting component, then its dose is reduced based on the study protocol. No food intake (water is allowed) until there is onset of mild hypoglycemia, determined by a capillary blood glucose test result 3.0 to 3.8 mmol/L. Based on each participant's own experience with hypoglycemia treatment or their preferences, the participant can choose one of 4 simple carbohydrate treatment quantities: 8 grams, 16 grams, 20 grams, 32 grams The participant can choose one of 4 capillary blood glucose recheck times: 15 minutes, 20 minutes, 25 minutes, 30 minutes.

Primary Outcomes

  • To determine feasibility to recruit an average of 8 patients per month at the study site (The Ottawa Hospital Diabetes clinics) for study protocol performance. (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-07-21
Completion: 2027-06-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ottawa Hospital Research Institute
Principal Investigators:
  • Cathy Sun, MD MSc (PRINCIPAL_INVESTIGATOR) - Ottawa Hospital Research Institute
Contact Information
Study Contact:
Cathy Sun, MD MSc
613-738-8333
csun@toh.ca
Cathy Sun, MD MSc
613-738-8333
csun@toh.ca
The Ottawa Hospital
Cathy Sun, MD MSc
The Ottawa Hospital
Interventions
  • Behavioral: Recumbent Exercise Bike to induce mild hypoglycemia — The participant rides the recumbent exercise bike at their preferred speed and records the distance travelled until there is onset of mild hypoglycemia, determined by capillary blood glucose test result 3.0 to 3.8 mmmol/L. Based on each participant's own experience with hypoglycemia treatment or their preferences, the participant can choose one of 4 simple carbohydrate treatment quantities: 8 grams, 16 grams, 20 grams, 32 grams The participant can choose one of 4 capillary blood glucose recheck times: 15 minutes, 20 minutes, 25 minutes, 30 minutes.
  • Behavioral: Delaying food to induce mild hypoglycemia, — At the study visit, in front of the study nurse, the participant takes their usual clinical care dose of sulfonylurea or basal insulin. If the participant's usual clinical care includes insulin with a rapid-acting component, then its dose is reduced based on the study protocol. No food intake (water is allowed) until there is onset of mild hypoglycemia, determined by a capillary blood glucose test result 3.0 to 3.8 mmol/L. Based on each participant's own experience with hypoglycemia treatment or their preferences, the participant can choose one of 4 simple carbohydrate treatment quantities: 8 grams, 16 grams, 20 grams, 32 grams The participant can choose one of 4 capillary blood glucose recheck times: 15 minutes, 20 minutes, 25 minutes, 30 minutes.
Study Locations (1 sites)
The Ottawa Hospital, Ottawa, Ontario K1H 7W9 Canada
Eligibility Criteria
Inclusion Criteria: * In order to be eligible to participate in this study, an individual must meet all of the following criteria: 1. Consent provided 2. Age \>= 18 years. 3. Diagnosed as type 2 diabetes mellitus. 4. Type 2 diabetes medications include at least one of the following for at least one month prior to entering the study: sulfonylurea or insulin of any type. Exclusion Criteria: * An individual who meets any of the following criteria will be excluded from participation in this study: 1. Diagnosed as another form of diabetes mellitus. 2. Has a history of hypoglycemia unawareness. 3. Had a hypoglycemia event, defined as capillary blood glucose \< 3.9 mmol/L within 24 hours prior to the study visit booking time.
Conditions Depressive Symptoms, Anxiety, Stress
Phase NA
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

In recent years, university education has become more challenging due to increased academic competition. A rising number of university students globally are currently being diagnosed with mental health problems, and previous research suggests that insufficient social support plays a significant role in the development of mental illnesses, such as symptoms of depression and anxiety. Music Therapy has been widely used in emotional regulation, offering a promising solution for people struggling with anxiety, depression, and social isolation. Research on the neural mechanisms underlying music therapy represents rapidly growing field of study. Hyperscanning is one of the useful neuroscience study methods, which is widely-used for study interbrain synchronization, refers to the simultaneous measurement of brain activity in two or more individuals who are interacting with each other. This study aims to investigate the effectiveness of music therapy intervention in enhancing mental health and social skills of university students with depressed, anxious, and stress symptoms. This current study will adopt a 2-arm randomized controlled design comparing therapeutic songwriting (experimental condition) with non-therapeutic music listening and discussion (control condition). Upon screening for inclusion criteria, baseline data will be collected; and eligible participants will be randomized into either 4 individual music therapy sessions or non-therapeutic music listening and discussion sessions.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Behavioral: Music Therapy Songwriting Intervention — The music therapy songwriting intervention is an active, client-centered music therapy approach in which the participant collaboratively create an original song with a professional music therapist. This evidence-based method combines: 1) lyric writing: the participant can express personal experience/emotions through guided lyric creation; 2) musical composition: the participant will choose or improvise their favorite melody, harmony, and rhythm with a music therapist; 3) therapeutic processing: discussion of song meaning and emotional connections between the participant and music therapist.

Primary Outcomes

  • Change of Baseline Depression Anxiety Stress Level after 4 Sessions (Baseline (day 1), and the last session (up to 2 weeks, the 4th session))
  • Change of Baseline Social Connection Level after 4 Sessions (Baseline (day 1), and the last session (up to 2 weeks, the 4th session))
  • Interbrain Synchrony Level During 4 Sessions (EEG-based) (Baseline (day 1), the 2nd session (3 days after the first session), the 3rd session (at the beginning of the second week) , the 4th session (3 days after the 3rd session, up to two weeks).)
  • Change of Baseline Hospital Anxiety and Depression Scale (Baseline (day 1), and the last session (up to 2 weeks, the 4th session))
  • Change of Baseline Perceived Stress Level (Baseline (day 1) and the last session (up to 2 weeks, the 4th session))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-02-10
Completion: 2025-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The University of Hong Kong
Principal Investigators:
  • Wanru Zhao (PRINCIPAL_INVESTIGATOR) - The University of Hong Kong
Contact Information
Study Contact:
Wanru Zhao
(852)59745737
wanru@connect.hku.hk
Wanru Zhao
(852)59745737
wanru@connect.hku.hk
2/F., The Hong Kong Jockey Club Building for Interdisciplinary Research
Interventions
  • Behavioral: Music Therapy Songwriting Intervention — The music therapy songwriting intervention is an active, client-centered music therapy approach in which the participant collaboratively create an original song with a professional music therapist. This evidence-based method combines: 1) lyric writing: the participant can express personal experience/emotions through guided lyric creation; 2) musical composition: the participant will choose or improvise their favorite melody, harmony, and rhythm with a music therapist; 3) therapeutic processing: discussion of song meaning and emotional connections between the participant and music therapist.
Study Locations (1 sites)
2/F., The Hong Kong Jockey Club Building for Interdisciplinary Research, Hong Kong, Hong Kong
Eligibility Criteria
Inclusion Criteria: * (1) adults who aged between 18-40 * (2) without any mental diagnosis * (3) able to speak and read Mandarin, Cantonese, or English * (4) moderate stress or problems in academic activities, problems in interpersonal relationships, or adaptability to college life. * (5) participants DASS-21 score \>= "Moderate" severity on each subscale (Depression \>= 14; Anxiety \>= 10; Stress \>= 19). Exclusion Criteria: * (1) has more than 10 consecutive years professional music training * (2) with chronic illness and taking medication * (3) with prior history of brain trauma or brain surgery * (4) wearing metal piercings or implants.

Food and Fitness With Medicine (FFWM)

NCT07027995
Recruiting
Conditions Cardiovascular Kidney Metabolic Syndrome...
Phase NA
Enrollment 200
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Food and Fitness with Medicine (FFWM) is a 24-week randomized controlled trial (RCT) enrolling 200 post-menopausal women (PMW) with stage 2 cardio-kidney metabolic (CKM) syndrome and type-2 diabetes (T2D) within 6 weeks of initiating glucagon-like peptide-1 receptor agonist (GLP-1RAs) to: 1. Examine discontinuation rates of GLP-1RAs (primary outcome); 2. Compare change in American Heart Association (AHA) PREVENT scores (secondary outcome); and 3. Examine the effects of FFWM on biologic mechanisms responsive to weight loss and cardiovascular health (CVH) including dermal carotenoids, body composition and metabolite biomarkers.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: Exercise is Medicine (EIM) — During Phase 1 (Weeks 1-12), participants are enrolled in a comprehensive 12-week fitness education and training program.
  • Behavioral: Culinary Education — During Phase 1 \& 2, participants receive monthly hybrid cooking demonstrations with culinary training.
  • Behavioral: Food is Medicine — During Phase 1 (Weeks 1-12), participants receive bi-weekly medically tailored grocery vouchers.
  • Behavioral: Nutrition Counseling — During Phase 1 (Weeks 1-12), participants engage in weekly behavioral nutrition counseling.
  • Behavioral: Participant Website — During Phases 1 and 2, participants will receive digital behavioral reinforcers and access to a secure web portal that provides evidence-based resources.

Primary Outcomes

  • GLP-1 RA discontinuation rates (0, 12, and 24 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-01-14
Completion: 2029-03
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ohio State University
Collaborators: American Heart Association
Principal Investigators:
  • Colleen K Spees, PhD, MEd, RD (PRINCIPAL_INVESTIGATOR) - Ohio State University
Contact Information
Study Contact:
Jenna N Hauben, BS
9083344689
jenna.hauben@osumc.edu
Cara L Chase, BS
5032789721
cara.chase@osumc.edu
Luiza Reopell, MBA
614-572-9191
luiza.reopell@osumc.edu
Ohio State East Hospital
Interventions
  • Behavioral: Exercise is Medicine (EIM) — During Phase 1 (Weeks 1-12), participants are enrolled in a comprehensive 12-week fitness education and training program.
  • Behavioral: Culinary Education — During Phase 1 \& 2, participants receive monthly hybrid cooking demonstrations with culinary training.
  • Behavioral: Food is Medicine — During Phase 1 (Weeks 1-12), participants receive bi-weekly medically tailored grocery vouchers.
  • Behavioral: Nutrition Counseling — During Phase 1 (Weeks 1-12), participants engage in weekly behavioral nutrition counseling.
  • Behavioral: Participant Website — During Phases 1 and 2, participants will receive digital behavioral reinforcers and access to a secure web portal that provides evidence-based resources.
Study Locations (4 sites)
Ohio State Healthy Community Center, Columbus, Ohio 43062 United States
Ohio State East Hospital, Columbus, Ohio 43203 United States
Martha Morehouse, Columbus, Ohio 43221 United States
Ohio State Outpatient Care Upper Arlington, Upper Arlington, Ohio 43221 United States
Eligibility Criteria
Inclusion Criteria: * Diagnosis of at least one of the following conditions: hypertension, type 2 diabetes, hyperlipidemia, chronic kidney disease, and/or metabolic syndrome. * At least 18 years of age at the time of signing consent. * Participants must have reliable transportation to attend Exercise is Medicine sessions. * Access to an internet-enabled device. * No objections to online grocery shopping, home food deliveries, or nutrition counseling. * Residence meets Instacart delivery requirements (e.g., non-institutionalized). * Participant is willing to use a personal credit card for Instacart back-up payments. * Participants must speak English to be able to consent and engage in FIM and EIM programs. * Participant has been clinically prescribed GLP-1RA's. Exclusion Criteria: * Conditions that impact digestion, metabolism, or food intake (e.g. surgical loss of esophagus, stomach, or colon, pancreatic dysfunction, bariatric surgery, brain surgery that alters cognition, etc.). * Participants with uncontrolled mental illness disorders (e.g., schizophrenia, bipolar disorder, major depression, etc.) that are not well-managed or controlled through treatment, as determined by the study team. * Familial history of certain cancers (e.g., multiple endocrine neoplasia, medullary thyroid carcinoma, etc.). * Active digestive illnesses (i.e., Celiac disease, irritable bowel syndrome, chronic malabsorption). * Comorbidities such as psychiatric or general illness that may put the subject at risk as determined by the investigator/s. * Renal impairment, eGFR \< 60 ml/min/1.73m2 * Factor which, in the investigator's opinion, is likely to compromise the subject's ability to participate in the study. * Recent participation (e.g., 3 months) in other behavioral nutrition trials or programs (i.e., bariatric programs, diabetes education programs). * Currently pregnant or planning to become pregnant during the study. * Participant is not willing to provide a urine, blood, or stool sample.
Conditions Perinatal Mental Health
Phase NA
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The perinatal period is recognized as a time of heightened psychological vulnerability. This research aims to improve the diagnosis and therapeutic management of mood episodes occurring during this time. It is integrated into routine clinical care and seeks to standardize the evaluation of criteria used to characterize mood episodes, while also exploring relevant contextual factors. Traditionally, clinical attention has focused on postnatal depression; however, increasing evidence highlights the presence of hypomanic symptoms-such as distractibility, reduced need for sleep, tachypsychia, and irritability-during the postpartum period. These symptoms may coexist with depressive features, resulting in complex clinical presentations that are often difficult to recognize and manage. Consequently, many cases go undiagnosed and untreated. Current research has largely concentrated on depressive episodes (perinatal depression), with less emphasis on manic, hypomanic, or mixed episodes indicative of bipolar disorder. A systematic evaluation of hypomanic symptoms occurring alongside depressive symptoms in the postpartum period could refine clinical diagnosis and support more targeted and effective therapeutic interventions.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Other: self-questionnaires — Patients who volunteer to take part in the research will complete self-questionnaires before their appointment with the psychiatrist.

Primary Outcomes

  • Detailed description of the Edinburg Postnatal (EPDS) scale (1 day)
  • Detailed description of Multidimensional Assessment of Thymic (MAThyS) scale (1 day)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-13
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Centre Hospitalier Charles Perrens, Bordeaux
Principal Investigators:
  • Anne-Laure SUTTER-DALLAY, Prof Md PhD (PRINCIPAL_INVESTIGATOR) - Centre Hospitalier Charles Perrens
Contact Information
Study Contact:
Anne-Laure SUTTER DALLAY, Prof, MD, PhD
+33 556561782
alsutter@ch-perrens.fr
Helen SAVARIEAU
+33556563556
hsavarieau@ch-perrens.fr
Helen SAVARIEAU
+33556563556
hsavarieau@ch-perrens.fr
Centre Hospitalier CHARLES PERRENS
Interventions
  • Other: self-questionnaires — Patients who volunteer to take part in the research will complete self-questionnaires before their appointment with the psychiatrist.
Study Locations (1 sites)
Centre Hospitalier CHARLES PERRENS, Bordeaux, New Aquitaine 33076 France
Eligibility Criteria
Inclusion Criteria: * Women over 18 years old * Pregnant or having given birth less than a year ago * First psychiatric consultation for the pregnancy concerned. * Good command of the French language. * Participant affiliated to the social security system * Participant who has given her consent to take part in the study. Exclusion Criteria: * Women who gave birth more than a year ago. * Participant under psychiatric care * Participant under court protection
Conditions Breast Cancer Female
Phase Not Applicable
Enrollment 42
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Breast cancer is one of the most common types of cancer among women and one of the leading causes of morbidity and mortality. With increasing survival rates, issues such as treatment-related morbidities and consequently upper extremity dysfunction, reduced body awareness, and decreased quality of life are frequently encountered. In the literature, the impact of treatment-related morbidities-particularly on upper extremity functions, body awareness, and quality of life-among women who have survived breast cancer treatment has not been sufficiently investigated. This gap constitutes a significant shortcoming in terms of clinical practices and the post-treatment period. This study aims to examine the effects of breast cancer treatment on upper extremity functions, body awareness, and quality of life in women who have survived breast cancer treatment, in comparison with a healthy control group. The study will be conducted at Yeditepe University Koşuyolu Hospital between May, 2025, and October, 2025. Participants will include women who have survived breast cancer treatment and a healthy control group matched based on criteria such as age and body mass index. In the study, three separate assessments will be conducted for upper extremity functions: the "Quick Disabilities of the Arm, Shoulder, and Hand" (QuickDASH) questionnaire for upper extremity functionality, a hand dynamometer for grip strength, and the Clinometer device for shoulder joint position sense. The "Body Awareness Questionnaire" will be used to assess body awareness, and the "EORTC QLQ-C30" scale will be used for quality of life assessment. The IBM SPSS Statistics software package will be used for data analysis. In statistical analyses, a significance level of p\<0.05 will be considered.

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Primary Outcomes

  • Body Awareness Scale (At the day of enrollment)
  • Disabilities of the Arm, Shoulder and Hand (DASH) Questionnaire (At the day of enrollment)
  • Hand Grip Strength Assessment (At the day of enrollment)
  • Shoulder Joint Position Sense (At the day of enrollment)
  • European Organisation for Research and Treatment of Cancer Questionnaire (At the day of enrollment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-05-06
Completion: 2025-11-15
Eligibility
Age: 25 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 42 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Halic University
Principal Investigators:
  • Seda Saka, PhD (STUDY_DIRECTOR) - Haliç University
Contact Information
Study Contact:
Seda Saka, PhD
05447803417
sedasaka@halic.edu.tr
Seda Saka, phd
00905447803417
sedasaka@halic.edu.tr
Halic University
Dilek Şahinoğlu
dileksahinoglu@halic.edu.tr
Halic University
Interventions
N/A
Study Locations (2 sites)
Halic University, Istanbul, Turkey (Türkiye)
Yeditepe Hospital, Istanbul, Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria for breast cancer survivors: * Being a woman * Being between the ages of 25 and 75 * Having been diagnosed with Stage 0-III breast cancer * Having completed primary treatments (surgery, chemotherapy, and/or radiation therapy) no more than 6 months prior to the assessment date * Having received medical clearance from a physician * Having undergone either breast-conserving surgery or mastectomy due to breast cancer * Willingness to participate in the study voluntarily Exclusion Criteria for breast cancer survivors: * Having a history of rehabilitation due to upper extremity, thoracic, or cervical musculoskeletal disorders within 6 months prior to the breast cancer diagnosis * Having a history of neuromuscular dysfunction * Using medications that may affect neuromuscular performance Inclusion criteria for the control group: * Being a woman * Having a body mass index (BMI) within ±3 kg/m² of the breast cancer survivor group * Being within ±5 years of age compared to the breast cancer survivor group * Matching hand dominance with the breast cancer survivor group Exclusion criteria for the control group: * Having a history of neuromuscular dysfunction * Using medications that may affect neuromuscular performance * Having a history of rehabilitation due to upper extremity, thoracic, or cervical musculoskeletal disorders within the last 6 months
Conditions Major Depressive Disorder (MDD), Suicida...
Phase NA
Enrollment 25
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn if a fast-acting brain stimulation treatment called transcranial magnetic stimulation (TMS) can help people with depression and suicidal thoughts. The treatment is non-invasive (does not involve surgery or medications), is given over 5 days, and uses brain imaging (MRI) to guide which part of the brain to target. This study tests whether this treatment is a helpful and practical option for adolescents and young adults who are depressed and have suicidal thoughts. We want to see if: 1. This treatment is feasible and acceptable to patients 2. It can reduce depression and suicidal thoughts 3. It can lower the chance of going to the hospital 4. It affects daily functioning (school, work, relationships) All participants will undergo 5-days of TMS treatment and complete MRI brain scans before and after treatment. They will return for check-ups after 1 week and 4 weeks.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: TMS — The protocol involves delivering sessions of intermittent theta burst stimulation (iTBS) of 60 cycles of 10 bursts of three pulses at 50 Hz were delivered in 2-second trains (5 Hz) with an 8-second intertrain interval. Stimulation sessions will be delivered hourly. Ten sessions will be applied per day (18,000 pulses/day) for 5 consecutive days (90,000 pulses in total). Stimulation will be delivered at 90% resting motor threshold (rMT).

Primary Outcomes

  • Change in MADRS score (1 week)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-07-01
Completion: 2027-05-31
Eligibility
Age: 15 Years and older
Sex: ALL
Volunteers: false
Enrollment: 25 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, Davis
Collaborators: Sorensen Foundation
Contact Information
Study Contact:
Se Ri (Sally) Bae, MD
213-340-4006
sebae@ucdavis.edu
Se Ri Bae, MD
916-244-0832
sebae@health.ucdavis.edu
UC Davis Medical Center
Interventions
  • Device: TMS — The protocol involves delivering sessions of intermittent theta burst stimulation (iTBS) of 60 cycles of 10 bursts of three pulses at 50 Hz were delivered in 2-second trains (5 Hz) with an 8-second intertrain interval. Stimulation sessions will be delivered hourly. Ten sessions will be applied per day (18,000 pulses/day) for 5 consecutive days (90,000 pulses in total). Stimulation will be delivered at 90% resting motor threshold (rMT).
Study Locations (1 sites)
UC Davis Medical Center, Sacramento, California 95817 United States
Eligibility Criteria
Inclusion Criteria: * English speaking * Able to provide informed consent * age 15-25 years * Discharged within the past week from the ED for chief complaint of SI OR recently admitted in urgent health care setting or seen in outpatient clinic for depression-related suicidal ideation * Meets MDD criteria per the Mini International Neuropsychiatric Interview (MINI) Exclusion Criteria: * Unable to consent (due to medical condition, psychosis, substance use, etc) * Use of benzodiazepines or medications that would interfere with TMS treatment as per PI discretion * Active substance use or severe substance use that in the opinion of the PI would interfere with study participation * Untreated, active psychosis * Female patient who is breastfeeding, pregnant or who is planning a pregnancy during the study * Participation in any clinical study with exposure to any investigational treatment or product within the previous 30 days, or plan on concurrent participation in other studies * Contraindications to receiving TMS and/or MRI as determined by screening questionnaires
Conditions Depression - Major Depressive Disorder
Phase PHASE2
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This research study aims to understand how people with depression respond to the medication pramipexole and to determine whether clinical response differs depending on the function of specific circuits in the brain. The investigators hope to learn which circuits are involved in depression and how these circuits interact with pramipexole to affect mood, behavior, and cognition. Eligible participants will undergo an 8-week treatment course of pramipexole followed by a 2-week down taper and follow up. The ultimate goal is to offer people experiencing depression a medication that is alternative to ones that may not have worked in the past and to apply the knowledge the investigators gain from investigating the brain circuits involved in depression to help personalize treatment. The investigators invite anyone who has recently experienced symptoms of depression to participate. A prior diagnosis of depression is not required.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Pramipexole Immediate Release — The intervention involves taking pramipexole immediate release (IR) for 8 weeks followed by 2 weeks of down titration and follow up.

Primary Outcomes

  • QIDS-SR: Quick Inventory of Depressive Symptomatology Self-Report (8 weeks)
  • MASQ-30: Mood Anxiety Symptom Questionnaire (8 weeks)
  • Brain imaging (8 weeks)
  • Cognitive-Emotional Behavioral Assessment (8 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-01-23
Completion: 2030-08
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Stanford University
Collaborators: National Institute of Mental Health (NIMH)
Contact Information
Study Contact:
Isabelle Wydler
(650)-736-4393
iwydler@stanford.edu
Daniella Evangelista
danevan@stanford.edu
Isabelle Wydler
650-736-4393
iwydler@stanford.edu
Stanford University
Interventions
  • Drug: Pramipexole Immediate Release — The intervention involves taking pramipexole immediate release (IR) for 8 weeks followed by 2 weeks of down titration and follow up.
Study Locations (1 sites)
Stanford University, Palo Alto, California 94305 United States
Eligibility Criteria
Inclusion Criteria: * 18-65 years old (inclusive) * Fluent and literate in English, with non-impaired intellectual abilities to ensure adequate comprehension of the task instructions. * Willing to provide written, informed consent. * Functional magnetic resonance imaging (fMRI) scanning eligibility. All participants will need to successfully complete the screening forms at the Stanford Center for Cognitive and Neurobiological Imaging (CNI). * Patient Health Questionnaire-8 (PHQ-8) \>/= 10 * Meet the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) diagnostic criteria for current or recurrent nonpsychotic Major Depressive Disorder (MDD) established by the Mini International Neuropsychiatric Interview (MINI) Exclusion Criteria: * Suicidality with active plan or as determined clinician judgment * Current or lifetime history of medical illness or brain injury that may interfere with assessments as determined by clinician judgment * Severe impediment to vision, hearing, and/or hand movement likely to interfere with ability to complete the assessments, or is unable and/or unlikely to follow the study protocols as determined by clinician judgment * Pregnant, breastfeeding or unwilling or unable to use adequate birth control throughout the study * History of non-responsive depression to dopamine agonists * Any contraindication to being scanned in the 3.0T fMRI scanner, such as a cardiac pacemaker or implanted device that has not been cleared for scanning * Previous or current DSM-5 bipolar disorder (I, II, not otherwise specified), schizophrenia spectrum or other psychotic disorders, or psychosis or as determined by clinician judgment * Previous or current diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD) * Meeting DSM-5 criteria for current Obsessive-Compulsive Disorder (OCD) or eating disorder * Meeting DSM-5 criteria for alcohol use disorder or substance use disorder within the last 12 months * Clinically significant presence/history of impulsive-compulsive behaviors or control disorder including but not limited to gambling disorder within the last 12 months. * Current use or use of psychotropic medication within the past month. (If the participant's usual treating clinician agrees with discontinuing the medication, participants may enroll after tapering off the medication under the supervision of either their usual clinician or the study clinician. A washout period of 5 half-lives-or a different duration as determined by the study clinician-must be completed before the first scan.) * Concurrent participation in other intervention or treatment studies
Conditions Breast Carcinoma
Phase Not Applicable
Enrollment 1500
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational study is to determine the proportion of patients who are lost-to-follow-up at five years, identify factors associated with loss of follow-up , and explore patient-reported barriers to follow-up in a public sector cancer care setting. The main question it aims to answer is : Do proactive outreach programs help in improving follow-up rates among breast cancer patients who are categorized as "lost-to-follow-up." This study will be conducted in a real-world cohort of women with non-metastatic breast cancer treated at a tertiary care centre, between 2017-2018.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Improvement in follow-up data with proactive outreach (6 months)
  • Updated mortality data (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-05-01
Completion: 2025-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Basavatarakam Indo American Cancer Hospital & Research Institute
Principal Investigators:
  • Nisha Hariharan, MS,HBNI Fellow Breast Oncology (PRINCIPAL_INVESTIGATOR) - Basavatarakam Indo American Cancer Hospital & Research Institute
Contact Information
Study Contact:
Clinical Trial Co-ordinator, Pharm D
040-23551235
research.oncology@basavatarakam.org
Clinical Trial Manager, B. Pharm
022-23551235
research.oncology@basavatarakam.org
Basavatarakam Indo American Cancer Hospital & Research Institute
Interventions
N/A
Study Locations (1 sites)
Basavatarakam Indo American Cancer Hospital & Research Institute, Hyderabad, Telangana 500034 India
Eligibility Criteria
Inclusion Criteria: 1. Patients newly diagnosed with non-metastatic breast cancer between 2017-2018 2. Patients categorized as "lost-to-follow-up", as defined above 3. Patients willing to participate upon re-engagement Exclusion Criteria: 1. Patients with incomplete medical records 2. Patients who have taken part of the treatment at another hospital/centre 3. Patients who have relocated permanently out of the study region Withdrawal Criteria: 1\. Patient withdraws consent
Conditions Breast Cancer, Medico-economic Impact, B...
Phase Not Applicable
Enrollment 772
Locations 7 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

MAGNETO is a French medico-economic study on preoperative localization in breast cancer surgery. The main objective is to conduct a cost-consequence analysis comparing magnetic clip localization with the use of metallic wires for the preoperative identification of non-palpable breast lesions. The choice of localization method is left to the physician's and center's discretion. The study is non-interventional (with only questionnaires and data collection), prospective, and multicenter, with patient follow-up lasting up to six months after breast surgery.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Procedure: magnetic clip localization — magnetic clip localization for preoperative localization for breast cancer surgery
  • Procedure: metallic wire localization. — metallic wire localization for preoperative localization for breast cancer surgery
  • Procedure: Breast cancer surgery — Patient with invasive or in situ breast carcinoma, presenting with a unifocal and unilateral lesion, requiring a first-line breast-conserving treatment with preoperative localization, regardless of the associated lymph node procedure

Primary Outcomes

  • Comparison of the average total cost of patient care with magnetic clip localization versus the use of a hookwire, up to 6 months post-surgery (6 months post surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-04-15
Completion: 2027-10-15
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 772 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Centre Leon Berard
Contact Information
Study Contact:
Severine Metzger
+33 (0)4 78 78 27 86
severine.metzger@lyon.unicancer.fr
Marie Osdoit, Dr
Marie.OSDOIT@lyon.unicancer.fr
Marion CORTET, Dr
+33 (0)4 72 11 80 88
marion.cortet@chu-lyon.fr
Hospices Civils de Lyon Hopital de la Croix rousse
Interventions
  • Procedure: magnetic clip localization — magnetic clip localization for preoperative localization for breast cancer surgery
  • Procedure: metallic wire localization. — metallic wire localization for preoperative localization for breast cancer surgery
  • Procedure: Breast cancer surgery — Patient with invasive or in situ breast carcinoma, presenting with a unifocal and unilateral lesion, requiring a first-line breast-conserving treatment with preoperative localization, regardless of the associated lymph node procedure
Study Locations (7 sites)
Hospices Civils de Lyon Hopital de la Croix rousse, Lyon, 69004 France
Centre Léon Bérard, Lyon, 69008 France
Institut de Cancérologie de Lorraine (ICL), Nancy, 54519 France
Hôpital Nord -Ouest Val d'Oise (NOVO), Pontoise, 95300 France
Institut GODINOT, Reims, 51726 France
Centre Eugène Marquis, Rennes, 35042 France
Institut Gustave Roussy, Villejuif, 94805 France
Eligibility Criteria
Inclusion Criteria: * I1. Female aged ≥ 18 years; * I2. Patient presenting with a unifocal and unilateral lesion of invasive carcinoma or in situ; * I3. Indication for first breast-conserving treatment with the need for preoperative localization of the lesion, regardless of the associated lymph node procedure; * I4. Patient affiliated with a health insurance system; * I5. Non-opposition to the study. Exclusion Criteria: * E.1. Psychological, family, or sociological condition that may potentially compromise adherence to the treatment protocol and follow-up; * E.2. Bilateral surgery required; * E.3. Patient with metastatic breast cancer; * E.4. Multifocal or benign lesions; * E.5. Pregnant or breastfeeding patient; * E.6. Need for neoadjuvant treatment; * E.8. Patient under guardianship, curatorship, or deprived of liberty.
Conditions AMD - Age-Related Macular Degeneration, ...
Phase Not Applicable
Enrollment 22
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Purpose: The aim of this study is to evaluate the impact of visual rehabilitation in visually impaired patients with advanced AMD by the use of questionnaires on the anxiety and depression status. Study design: prospective observational study. The study is carried out at the IRCCS Fondazione G.B.Bietti and at the UO Visual Rehabilitation, S. Alessio - Margherita di Savoia. Study procedures: Visit 1 (screening visit, at IRCCS Fondazione Bietti) After signing the informed consent, all patients received a complete ophthalmological examination, non-invasive diagnostic tests as optical coherence tomography, autofluorescence and microperimetry, and have to complete the questionnaires on the state of anxiety and depression (GAD-7 and PHQ-9). Visit 2 (at the Sant'Alessio Institute) for a 60-day visual rehabilitation program scheduled in 5 group meetings. Visit 3 (end-of-study visit, at IRCCS Fondazione G.B. Bietti) complete ophthalmological examination, as per clinical practice, non-invasive diagnostic tests such as microperimetry, optical coherence tomography and autofluorescence and administration of the Patient Health Questionnaire-9 (PHQ-9) questionnaires for depression and the General Anxiety Disorder (GAD-7) questionnaires for anxiety.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: visual rehabilitation program — I. meeting: coin recognition II. meeting: reading stories and audio books' listening III. meeting: installation of APPs on their smartphones and tablets and use of voice assistant IV. meeting: management of "table" activities V. meeting: meeting with caregivers.

Primary Outcomes

  • Changes of anxiety and depression status in visually impaired patients with AMD undergoing visual rehabilitation program (12 weeks)
  • Changes of anxiety and depression status in visually impaired patients with AMD undergoing visual rehabilitation program (12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-12-02
Completion: 2026-12-02
Eligibility
Age: 55 Years and older
Sex: ALL
Volunteers: false
Enrollment: 22 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fondazione G.B. Bietti, IRCCS
Collaborators: Sant'Alessio - Margherita di Savoia
Contact Information
Study Contact:
Eliana Costanzo, MD
+390684009442
eliana.costanzo@fondazionebietti.it
Eliana Costanzo, MD
+390684009442
eliana.costanzo@fondazionebietti.it
IRCCS Fondazione G.B.Bietti
Interventions
  • Other: visual rehabilitation program — I. meeting: coin recognition II. meeting: reading stories and audio books' listening III. meeting: installation of APPs on their smartphones and tablets and use of voice assistant IV. meeting: management of "table" activities V. meeting: meeting with caregivers.
Study Locations (1 sites)
IRCCS Fondazione G.B.Bietti, Rome, Italy 00184 Italy
Eligibility Criteria
Inclusion Criteria: 1. Subjects ≥ 55 years 2. Moderate and severe visual impairment (BCVA ≥1/10 and ≤2/10) 3. Diagnosis of advanced non-exudative age-related macular degeneration (AMD) 4. Informed consent freely granted and acquired before the start of the study 5. Ability to understand and willingness to follow the study instructions and procedures Exclusion Criteria: 1. Visual impairment due to other ocular diseases 2. Mild visual impairment or partial or total blindness 3. Exudative age-related macular degeneration undergoing intravitreal drug treatment
Conditions Breast Carcinoma
Phase Not Applicable
Enrollment 85
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The aim of this study is to evaluate the added value of non-contrast abbreviated MRI protocol featuring ultra-high B value Diffusion Weighted Imaging to detect, characterize suspicious breast lesions and avoid using contrast.

Design

Study type: Observational Observational model: Other Time perspective: Prospective

Primary Outcomes

  • To evaluate the capability of detecting suspicious breast lesions using non-contrast enhanced MRI protocol featuring ultra-high B-value (20 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-05-10
Completion: 2026-12-30
Eligibility
Age: 30 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 85 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ain Shams University
Contact Information
Study Contact:
Ahmed Mohamed Aly
+201273726233
ahmedaly@med.asu.edu.eg
Ahmed Mohamed Aly
+201273726233
ahmedaly@med.asu.edu.eg
Ain Shams University
Interventions
N/A
Study Locations (1 sites)
Ain Shams University, Cairo, Abbasia Egypt
Eligibility Criteria
Inclusion Criteria: * • Women with suspicious breast mass (BIRADS 4a) * High risk women (Positive family history) * Women with suspicious axillary lymph nodes by Ultrasound * Women with dense breasts coming for MRI imaging. Exclusion Criteria: * • Contraindications to MRI * Pacemaker, cochlear implant, claustrophobia, ocular implants * Contraindications to contrast administration: * Elevated kidney functions * Women who haven't undergone reliable Mammogram \& Ultrasound * Women with prior treatment or intervention (e.g. biopsy) * Patients' refusal.
Conditions Diabetes Mellitus, Type 2
Phase NA
Enrollment 108
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

To evaluate the effect of meal replacement therapy on glucose control and other metabolic parameters in patients with uncontrolled type 2 diabetes. Methodology: This is an open-label, prospective, randomized control trial study. Study duration. August 2023 - March 2026. Study location. This study will be conducted at the Klinik Rawatan Keluarga and diabetes clinic Hospital Universiti Sains Malaysia. Source Reference : People with type 2 diabetes mellitus attending the Hospital Universiti Sains Malaysia. Study source population : People with type 2 diabetes mellitus attended Klinik Rawatan Keluarga and diabetes clinic Hospital Universiti Sains Malaysia during the study period.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: Double

Interventions / Regimen

  • Other: Meal replacement therapy — A serving of Contro Eazy Now is equivalent to 5 scoops (50g) contains 26.5g of carbohydrate, 10g of protein and 8.9g of fat. It supplies 215kcal of energy per serving

Primary Outcomes

  • To compare changes and differences of HbA1c over a 12-week period in patients with uncontrolled type 2 diabetes on oral hypoglycemic agents on meal replacement vs control group. (12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-11-01
Completion: 2026-03
Eligibility
Age: 30 Years and older
Sex: ALL
Volunteers: false
Enrollment: 108 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hospital Universiti Sains Malaysia
Collaborators: Ethos Healthcare Sdn Bhd company
Principal Investigators:
  • Nani Draman, Masters (PRINCIPAL_INVESTIGATOR) - Professor
  • Siti suhaila, Masters (STUDY_CHAIR) - DR
  • NG Ying ying, Masters (STUDY_CHAIR) - DR
Contact Information
Study Contact:
kanmani kumaran, MD
+60135125136
kanmanikumaran@yahoo.com
Nani Draman, Masters
+601115184421
drnani@usm.my
kanmani kumaran, MD
+60135125136
kanmanikumaran@yahoo.com
Hospital Universiti Sains Malaysia
Interventions
  • Other: Meal replacement therapy — A serving of Contro Eazy Now is equivalent to 5 scoops (50g) contains 26.5g of carbohydrate, 10g of protein and 8.9g of fat. It supplies 215kcal of energy per serving
Study Locations (1 sites)
Hospital Universiti Sains Malaysia, Kubang Kerian, Kelantan 16150 Malaysia
Eligibility Criteria
Inclusion Criteria: 1. Patients between ≥ 30 to ≤ 65 years old 2. Diagnosed as having type 2 diabetes mellitus base on CPG Malaysia Clinical Practice Guidelines (CPG) for Type 2 Diabetes Mellitus (T2DM) 6th edition 2020. 3. On oral hypoglycaemic agent(s) 4. HbA1c 7- 10 % (result 3 months from the date of recruitment) 5. Agree not to take other beverages, herbal or nutritional supplements for the duration of the study. Exclusion Criteria: 1. Severe diabetic complication(s) including end-stage renal disease and proliferative retinopathy. 2. Pregnancy or plan to get pregnant during the study period 3. Newly diagnosed diabetic less than 3 months from the date of recruitment 4. Currently involve in any weight loss program 5. Currently consuming any meal replacement product 6. Patients with chronic kidney disease with eGFR ≤ 25 ml/min. 7. Patients with advanced liver disease, such as non-alcoholic steatohepatitis (NASH) with significant fibrosis (e.g., liver stiffness measurement \> 9.5 kPa by FibroScan) or cirrhosis. 8. Patients with significantly elevated liver enzymes (e.g., ALT or AST ≥ 3 times the upper limit of normal), which may indicate more severe liver damage.